- Trade Name: Epidiolex (GW Research Ltd)
- Indications: treatment of seizures associated with Lennox-Gastaut syndrome or Dravet syndrome in patients 2 years of age and older
- Synonym: CBD
- Half-life: 56–61 hours
- FDA Approval Date: 06/25/2018
- Clinically important, potentially hazardous interactions with:
Clobazam - Pregnancy: may cause fetal harm
Please login to view the rest of this drug profile.
Page last updated 09/22/2026
